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Methods: Interferon-gamma ELISpot assay was used in HIV uninfected persons with latent and
active tuberculosis to map peptide epitopes of Rv2654c. A modified IGRA was tested in two
further groups of 55 HIV uninfected and 44 HIV infected persons, recruited in South Africa.
Results: The most prominently recognised peptide was between amino acids 51e65. Using p51-
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Despite the worldwide availability of vaccination, diagnosis
and treatment, tuberculosis (TB) is still a major global
health problem and it is estimated that more than one-third
of the world’s population is infected by Mycobacterium
tuberculosis (MTB).1 Exposure to MTB may result in latent
TB infection (LTBI) which is defined by the absence of clin-
ical TB symptoms but carries about 5e10% lifetime risk of
developing active TB and comprises a significant reservoir
of future cases of active disease, particularly in countries
with high HIV burdens.2 The estimated incidence of TB is
9 million each year, among which 1.5 million cases die.
HIV infected patients are about 30 times more likely to
develop active TB and HIV-TB co-infection is responsible
for one fifth of all TB related deaths.
The currently used vaccine e Mycobacterium bovis Ba-
cille Calmette Gue´rin (BCG) e does not protect adults
against TB.3 Moreover, BCG vaccination renders the TB
diagnosis more difficult as the commonly used tuberculin
skin test (TST), based on the administration of purified pro-
tein derivative (PPD), may give false-positive results due to
previous BCG immunization.4
Proteins encoded at loci missing from BCG5,6 have
become of interest for TB diagnosis. Such regions of differ-
ence (RD), by definition, are absent from all BCG vaccine
strains.7 Comparative genomic studies have identified 11 re-
gions of difference of which RD1 contains important immu-
nodominant proteins such as ESAT-6 (Rv3875) and CFP-10
(Rv3874).8 These proteins showed reliable diagnostic poten-
tial in T-cell based IFN-g release assays (IGRAs) and are used
as antigens in FDA approved and commercially available
blood tests such as QuantiFERON-TB Gold In-Tube (QFT)
and T-SPOT.TB.9 ESAT-6 and CFP-10 are early secreted pro-
teins which form a heterodimeric complex10 and contribute
to the virulence of MTB.11 However, genes for ESAT-6 and
CFP-10 were found not only in MTB but also in virulent M.
bovis, and in several non-tuberculous mycobacteria.12,13
Thus, infection with such ESAT-6 or CFP-10 expressing myco-
bacterial species can result in a false-positive response in
blood tests based on ESAT-6 and CFP-10 antigens.
MTB sensitizationwas traditionally describedwith amodel
of binary distribution between active TB and latent TB.
Evidence supports that the interaction between MTB and the
host immune system represents a spectrum of immune
responses, bacterial load, metabolic activity and stages of
infection ranging from sterilizing immunity to TB disease.14,15
Suchheterogeneitymayexplain the fact thatantigens thatare
targets of the immune response in latent TB are frequently
found as target in active TB and no adequate differentiation
between latent and active disease has been revealed.16,17
Insufficient sensitivity of IGRA tests could be further
enhanced with the use of more antigens derived from
different immunodominant proteins of MTB. Previousstudies have demonstrated that Rv2654c can improve spe-
cific immune-based diagnosis of TB infection especially in
the BCG-vaccinated population18,19 and one peptide (p38-
55) has been included in the commercially available
QuantiFERON-TB Gold In-Tube (QFT) test. Rv2654c is an
81 amino acid alanine-rich protein, encoded in the RD11 re-
gion, highly specific for MTB and absent from most of the
atypical mycobacteria. We performed a systematic epitope
mapping of the Rv2654c protein and found that the most
immunogenic peptide recognized by MTB sensitized individ-
uals in South Africa is different from that previously
described by Aagaard and co-workers.18 We describe the
evaluation of a modified QuantiFERON-TB Gold In-Tube
test in HIV infected and uninfected cohorts.
Materials and methods
MHC-binding predictions
The amino acid sequence of Rv2654c protein was down-
loaded from the TubercuList20,21 website (http://
tuberculist.epfl.ch/index.html). In silico identification of
immunogenic regions of the Rv2654c protein was based on
predicting the MHC-binding affinity of 15-mer peptides
overlapping by 14 amino acid residues, using the MHC II
binding prediction tool22,23 available at the Immune
Epitope Database (www.iedb.org).24 Binding affinities
were predicted for the 27 representative MHC II alleles rec-
ommended by Greenbaum and colleagues, based on study-
ing peptide binding to MHC supertypes25 and evaluated
based on the consensus percentile ranks. As suggested by
Paul and colleagues,26 15-mer peptides were sorted based
on the median value of the percentile ranks predicted for
each representative allele and the top scoring w20% were
identified as possible immunodominant epitopes.
Synthesis and analytical characterization of
peptides
Peptides were produced on solid phase with an automated
peptide synthesizer (Syro-I, Biotage, Uppsala, Sweden) using
standard Fmoc/tBu strategy. Peptides used in this study
contained an amide group at the C-terminus for stability
purposes. After cleavage, crude peptides were purified by
semi-preparative HPLC and analysed by mass spectrometry,
analytical HPLC and amino acid analysis (Table 1). Mass
spectrometric analyses were performed on a Bruker Esquire
3000 þ ion trap mass spectrometer (Bruker, Bremen, Ger-
many) equipped with electrospray ionization (ESI) source.
Samples were dissolved in a mixture of acetonitrile/
water Z 1/1 (v/v) containing 0.1% acetic acid and intro-
duced by a syringe pump with a flow rate of 10 mL/min.
The homogeneity of the compounds was checked by
Table 1 Sequence and characteristics of peptides used in this study.
Code Sequence Mav
calc.
Mav
a
meas.
Rt
b
[min]
p1-20 MSGHALAARTLLAAADELVG 1966.3 1966.1 31.7
p11-30 LLAAADELVGGPPVEASAAA 1821.1 1821.0 25.8
p21-40 GPPVEASAAALAGDAAGAWR 1837.0 1837.0 27.5
p31-50 LAGDAAGAWRTAAVELARAL 1982.3 1982.1 34.4
p41-60 TAAVELARALVRAVAESHGV 2019.3 2019.2 33.3
p51-70 VRAVAESHGVAAVLFAATAA 1910.2 1909.8 32.0
p61-81 AAVLFAATAAAAAAVDRGDPP 1925.2 1925.1 30.5
p38-55 AWRTAAVELARALVRAVA 1922.1 1922.2 41.5c
p51-65 VRAVAESHGVAAVLF 1523.8 1523.8 28.4
p55-70 AESHGVAAVLFAATAA 1483.8 1483.8 30.0
p61-75 AAVLFAATAAAAAAV 1286.7 1286.8 16.5d
p66-81 AATAAAAAAVDRGDPP 1422.7 1422.8 16.6d
a Average molecular mass measured by a Bruker Esquire 3000 þ electrospray mass spectrometer.
b Retention time on an analytical RP-HPLC using an Eurospher-100, C-18, 5 mm, 250  4 mm column; gradient: 5% B, 5 min; 5e60% B,
35 min.
c Gradient: 5% B, 5 min; 5e90% B, 45 min.
d Phenomenex Jupiter C-4, 5 mm, 250  4 mm column, gradient: 5% B, 5 min; 5e70% B, 35 min.
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system (Bad Homburg, Germany) using 1 mL/min flow rate
at room temperature. The gradient elution system consisted
of 0.1% TFA in water (eluent A) and 0.1% TFA in acetonitrile/
water Z 80/20 (v/v) (eluent B). Amino acid analyses were
performed on a Sykam Amino Acid S433H analyzer (Eresing,
Germany) equipped with an ion exchange separation column
and post-column derivatisation. Prior to analysis samples
were hydrolysed with 6 M HCl in sealed and evacuated tubes
at 110 C for 24 h. For post-column derivatisation the
ninhydrin-method was used. Peptides were stored dry until
reconstitution as 1 mg/mL stock solutions in 0.5% DMSO con-
taining PBS buffer.
Selection and description of participants
The University of Cape Town’s Faculty of Health Sciences
Human Research Ethics Committee approved this study
(REC 296/2007, REC 245/2009). Written informed consent
was obtained from all participants.
For epitope mapping of Rv2654c, patients with active TB
or latent TB infection (LTBI) were recruited at Ubuntu Clinic,
site B Khayelitsha, South Africa. All were of Xhosa ethnicity.
Active TB was defined by smear and/or culture positivity for
MTB from one or more sputum specimens. LTBI was defined
by an IFN-g ELISpot response to ESAT-6 or CFP-10 of 20 spot-
forming cells (SFC)/106 PBMC above background, in the
absence of clinical symptoms or radiographic abnormality
and with negative sputum smear and culture for M. tubercu-
losis. All subjects recruited for epitope mapping underwent
HIV counselling and testing, and positivity was an exclusion
criterion, together with pregnancy and age under 18 years.
For the evaluation of the boosting effect of peptide 51-
65 on the QuantiFERON-TB Gold In-Tube test, 55 HIV
uninfected and 50 HIV infected persons were recruited at
Ubuntu Clinic, Site B Khayelitsha, South Africa. HIV infected
patients were recruited at enrolment into the antiretroviral
treatment (ART) programme based on their eligibility (CD4þT cell count of 250 cells/ml or less), according to South Af-
rican national guidelines at the time. 30 ml venous blood
was collected for immunological analysis, as well as viral
load and CD4þ T cell count measured at day 0, 1 month, 3
months and 6 months of ART. Induced sputum was collected
at all time-points; six patients with positive MTB culture
were referred to TB treatment and excluded from further
follow up and analysis.
Cell culture and in vitro assays
Peripheral blood mononuclear cells (PBMC) were prepared
using standard Ficoll separation technique and were stored
in liquid nitrogen until used. The measurement of IFN-g by
ELISpot was performed as described previously27,28 using
the human Interferon-g ELISpotPRO kit (MABTECH, Nacka
Strand, Sweden). Briefly, 2.5  105 PBMC were plated in
200 mL of RPMI culture media supplemented with 10% FCS.
Antigenic stimuli were either Rv2654c peptides at 10 mg/
mL final concentration, or a pool of ESAT-6 (Rv3875, 5 mg/
mL) and CFP10 (Rv3874, 5 mg/mL) derived peptides. As pos-
itive control, anti-CD3 mAb CD3-2 at 100 ng/mL final con-
centration was used. ELISpot plates were read on an
Immunospot Series 3B Analyzer (Cellular Technology, Cleve-
land, OH, USA) and plates were retained for visual inspec-
tion and confirmation in the case of anomaly. Results are
quoted as spot forming cells per million PBMC (SFC/106
PBMC), with the background (unstimulated) values
subtracted.
The QuantiFERON-TB Gold In-Tube test was performed in
a Cellestis accredited laboratory according to the manu-
facturer’s instructions (QuantiFERON-TB Gold In-Tube, Cel-
lestis Ltd., Carnegie, Australia). The modified (peptide
boosted) QuantiFERON-TB Gold In-Tube test (QFTB) was
performed in parallel, using a second set of tubes (repre-
senting Nil, Antigen, Mitogen), with peptide 51-65 added at
5 mg/ml final concentration (determined based on dose
response experiments) in the laboratory. Tubes were
182 K. Horvati et al.incubated overnight and IFN-g measured as IU/ml, using
the commercial assay. The results were interpreted simi-
larly, using the manufacturer’s criteria for assay positivity
(0.35 IU/mL above nil).
In silico HLA-binding study
In an attempt to relate epitope predictions to our labora-
tory findings, binding affinities were also corrected for the
allele frequencies observed in the Xhosa population. Since
the most detailed description of HLA types in the Xhosa
population29 is based on serological testing, while predic-
tion tools are genotype-based, serotype frequencies were
interpreted as allele frequencies according to the conver-
sion matrix provided as Supplementary Table 1.
To estimate the portion of the Xhosa population ex-
pected to present the given epitope, we used a model,
where an individual’s antigen presenting cells (APCs) ex-
press both maternal and paternal HLA-DR and HLA-DQ
genes. The relative number of individuals expressing a
given combination of HLA loci was computed using the
HardyeWeinberg equation.30 Competition between peptide
epitopes was simulated according to two different sce-
narios, described in the supplementary information in
more detail. Based on these simulations, only the best
scoring peptides in a particular subpopulation were re-
garded as ‘MHC-binder’ peptides. The sum of all fractions
of the population, where the peptide scored as a ‘binder’,
was regarded as the portion of the whole population that is
able to present the peptide epitope. Results were visual-
ized with the help of the Matplotlib Python module.31
In addition to the Xhosa population, HLA frequencies
described in the Danish population (a source of donors for
testing the p38-55 peptide in a previous study18) were also
included in the analysis. The frequencies described by Lind-
blom and colleagues32 were downloaded from the Allele
Frequency Net Database (allelfrequencies.net).33 In this
case, a more simplified model was used for simulating the
population, omitting HLA-DR3/DR4 and HLA-DQ loci.
Statistical analysis
Data were analysed using GraphPad Prism v6 software (San
Diego, CA, USA). For analysis of statistical significance
(p < 0.05) the ManneWhitney U test was used for unpaired
data and the Wilcoxon matched pairs test was used for
paired data. Bonferroni correction was used to correct p
values for multiple comparisons where applicable.
Results
Identification of highly immunogenic regions by
MHC-binding predictions
The median value of the consensus percentile rank scores
of binding to supertype-defining HLA II alleles was obtained
from predictions by the IEDB webservice, for each 15-mer
peptide.26 As reflected by the median score for MHC bind-
ing, the highest binding peptides of the Rv2654c protein
were found to be in the middle section (starting aminoacid positions between 36 and 40) and the C-terminal sec-
tion with starting positions between 58 and 63 (Fig. 1).
Epitope mapping of Rv2654c protein
To validate and refine the in silico prediction, synthetic 20-
mer peptides, spanning the complete sequence of the
Rv2654c protein and overlapping by 10 amino acids, were
prepared and analysed in vitro (Table 1). A pool of overlap-
ping peptides, covering the sequence of Rv2654c, was used
as a substitute for the recombinant protein, as previous
studies have demonstrated antigenic equivalence of the
T-cell response between the recombinant proteins and
the corresponding synthetic peptide mixtures for ESAT-6,
CFP-10 and TB10.4.34,35
Altogether, PBMC from 34 individuals were used,
comprising 24 individuals with LTBI (median age 27 years,
14 female, 10 male) and 10 patients with active TB (median
age 27 years, 4 female, 6 male). Since all individuals were
MTB sensitized, and there was no differential recognition of
the peptides between LTBI and active TB patients in line
with published literature,16,17 results were combined for
analyses (Table 2). The frequency of recognition of the C-
terminal peptides p51-70 and p61-81 was comparable to
that of the Rv2654c pool in the combined groups (29% and
35% compared to 32% respectively). We therefore selected
the C-terminal 51e81 region of the protein for further char-
acterization, using shorter peptides.
For the detailed C-terminal analysis, 15-mer peptides
were prepared (Table 1), in order to fine map the 51e81
amino acid region. As control, the p38-55 peptide was
also prepared as this peptide is included in the
QuantiFERON-TB Gold In-Tube test (coded as TB7.7 p4). In
the combined group of 19 MTB sensitized individuals (repre-
senting a subset of the previously studied nZ 10 active TB
patients, and n Z 9 LTBI, selected based on availability of
frozen PBMC remaining after the first set of experiments),
the highest IFN-g response was seen to p51-65, with a me-
dian of 27 spot forming cells/million PBMC (SFC/106, IQR
12e85), recognized by 67% of all PBMC samples (Fig. 2).
This was significantly higher than the response to the previ-
ously described p38-55 peptide (median 8 SFC/106, IQR
0e12; pcorrZ 0.002, ManneWhitney U test with Bonferroni
correction), with only 11% of PBMC samples giving a positive
response. These results suggest that the most frequently
recognized epitope of Rv2654c protein in this population
is present within the 51e65 amino acid region.
Predicted epitope promiscuity in different test
populations
Since the method suggested by Sinu and colleagues does
not take differences in HLA frequencies in different
populations into account, we related epitope predictions
and our in vitro experimental findings to the population
tested. In order to achieve this, MHC binding scores of
the IEDB epitope prediction tool were corrected for the
serotype frequencies of the Xhosa population following a
stringent model. We found that only the region near the
C-terminal end of the protein was immunogenic enough to
show up in the analysis (Fig. 3A). If binding only to HLA-
Figure 1 Identification of highly immunogenic regions by MHC-binding predictions. The median value of the consensus percen-
tile rank scores of binding to supertype-defining HLA II alleles was obtained from predictions by the IEDB webservice, for each 15-
mer peptides.26 Since the smaller consensus percentile rank a peptide has, the better binding is expected, percentile rank values
were converted to binding scores by subtraction of the value from 100. The 100 minus median rank values are shown for the top
scoring 20% (15 peptides) as a function of starting residues.
Peptide boost of QuantiFERON-TB assay 183DR region was calculated, however, two highly immuno-
genic regions (starting at positions around 40 and around
60) could be detected (Fig. 3B). The location of these re-
gions was similar in case of both the Xhosa and the Danish
populations (Fig. 3C).
Boosting QuantiFERON-TB gold in-tube test with
peptide p51-65
We next evaluated the boosting effect of peptide p51-65 on
the QuantiFERON-TB Gold In-Tube (QFT) test in an HIV
uninfected (n Z 55) and an HIV infected (n Z 44) group of
patients, none of whom had any signs and/or symptoms of
active TB. The median age of the HIV uninfected partici-
pants was 26 (30 female, 25 male) and 33 for the HIV in-
fected (30 female, 14 male) patients. The median CD4þTable 2 Recognition of single peptides and Rv2654c peptide po
LTBI n Z 24 Active n Z 1
No. pos.
resp.a
Sensitivity %
(95% CI)b
Median
SFC/106
(IQR)c
No. pos.
resp.a
Sensit
(95%
p1-20 6/24 25 (9.8e46.7) 5 (0e19) 2/10 20 (2.
p11-30 1/24 4 (0.1e21.1) 0 (0e8) 1/10 10 (0.
p21-40 4/24 17 (4.7e37.4) 4 (0e10) 2/10 20 (2.
p31-50 6/24 25 (9.8e46.7) 6 (0e18) 2/10 20 (2.
p41-60 4/24 17 (4.7e37.4) 4 (0e8) 1/10 10 (0.
p51-70 7/24 29 (12.6e51.1) 4 (0e23) 3/10 30 (6.
p61-81 7/24 29 (12.6e51.1) 8 (0e20) 5/10 50 (18
Rv2654c
pool
7/24 29 (12.6e51.1) 6 (0e35) 4/10 40 (12
ESAT-6
/CFP-10
24/24 100
(85.8e100)
240
(82e419)
8/10 80
(44.4e
PBMC of either LTBI (n Z 24) or active TB patients (n Z 10) were in
entire sequence of Rv2654c protein using the ELISpot assay. The numb
and compared to ESAT-6/CFP-10 response. The cut-off for positive re
a Number of positive responders/number tested.
b Sensitivity was calculated as a ratio of the number of true positive
responders.
c Median spot number and interquartile range.T-cell count in the HIV uninfected cohort was 817 and 197
in the HIV infected group.
In the HIV uninfected group, the quantitative perfor-
mance of the QFT test increased significantly from a
median of 1.83 IU/ml (background e nil, IQR 0.30e7.35)
to 2.83 (IQR 0.28e12.2), p Z 0.002, Table 3. There was a
statistically non-significant change in the percentage of re-
sponders from 73% to 75%, and in sensitivity from 95% to
98%, due to the peptide boost.
In the case of the HIV infected cohort, the quantitative
performance of the QFT and modified QFTB did not differ at
day 0 of ART, with medians of 1.17 (IQR 0.26e7.14) and
1.17 IU/ml (IQR 0.05e6.11) respectively (Table 4). Howev-
er, 3 months into antiretroviral treatment (ART) the fre-
quency of positive responders increased from 57% to 64%
(statistically not significant) with 5 patients changing fromol by individuals with LTBI and active TB.
0 Combined n Z 34
ivity %
CI)b
Median
SFC/106
(IQR)c
No. pos.
resp.a
Sensitivity %
(95% CI)b
Median
SFC/106
(IQR)c
5e55.6) 3 (0e15) 8/34 24 (10.8e41.2) 4 (0e17)
3e44.5) 2 (0e6) 2/34 6 (0.7e19.7) 0 (0e8)
5e55.6) 9 (0e28) 6/34 18 (6.8e34.5) 4 (0e11)
5e55.6) 95e14 8/34 24 (10.8e41.2) 7 (0e14)
3e44.5) 2 (0e9) 5/34 15 (5.0e31.1) 4 (0e8)
7e65.3) 9 (0e26) 10/34 29 (15.1e47.5) 4 (0e21)
.7e81.3) 18 (5e46) 12/34 35 (19.8e53.5) 10 (0e24)
.2e73.8) 106e24 11/34 32 (17.4e50.5) 8 (0e24)
97.5)
109
(37e163)
32/34 94
(80.3e99.3)
156
(61e362)
vitro stimulated with 20-mer overlapping peptides spanning the
er of spot forming cells per million PBMC (SFC/106) are presented
sponse was 20 SFC/106.
responders over the number of false negative plus true positive
Figure 2 Detailed analysis of the C-terminal 51e81 region
of Rv2654c compared to p38-55 peptide. The number of spot
forming cells per million PBMC (SFC/106) are presented from
n Z 19 MTB sensitized individuals. The cut-off for positive
response was 20 SFC/106 above nil (dotted line). Significance
was calculated using ManneWhitney U test. **p < 0.005. Black
lines represent the median SFC/106 values on both panels.
184 K. Horvati et al.negative (QFT) to positive (modified QFTB) response. Of
these patients, 4 remained positive at 6 months of ART
(one was not tested at 6 months of ART, Supplementary
Table 2). Additionally, at 6 months another 3 patients
changed from negative to positive response due to the pep-
tide boost. Overall, at 6 months of ART, the frequency of
positive responders increased from 56% to 64% due to the
peptide boost, however, this increase was not statistically
significant. Additionally, we calculated sensitivities as a ra-
tio of the number of true positive responders over the num-
ber of false negative plus true positive responders. False
negativity is defined for those who had at least one positive
result before. We found an increased albeit not significant,
sensitivity (90% from 80% to 93%e81% at 3 and 6 months,
respectively) for QFTB compared to QFT.
Discussion
Peptide epitopes, which are minimal sequences of proteins
necessary for immune recognition, have attracted consider-
able attention as diagnostic reagents. Peptides are chem-
ically well-defined molecular entities that can be easily
synthesized in industrial scale and offer improved purity
and specificity. Furthermore, synthetic peptides are gener-
ally more stable than full-length proteins or whole organ-
isms, and they do not require refrigerated storage.
Therefore, epitope mapping of the Rv2654c protein was
evaluated with the aim to identify antigenic peptides that
can be used to induce a cytokine response in an IGRA-type
test. Our data indicate that more frequently recognised
peptides of Rv2654c in South Africa are in the C-terminal
region between amino acids 51e81. Further detailed
epitope mapping resulted in the identification of peptide
p51-65 which was the most dominantly recognised peptide
of the Rv2654c protein. It is interesting that when testingthe 20-mer peptides, the spot counts were higher for p61-
81 as compared to p51-70, which contains the p51-65
sequence. However, the % responders overall were high
for both peptides. The strength of peptide binding is influ-
enced by the flanking regions of the epitope and it is
possible that the p51-65 sequence allows stronger binding
of the epitope region as compared to p51-70. It is also likely
that the shared sequence between p61-81 and p51-65,
amino acids 61e65 are part of the epitope core, the binding
of which is more efficient in the context of the p51-65, in
stimulating T cell responses.
This finding contrasts with publications18,19 that identi-
fied p38-55 as the most potent antigenic peptide. Our
observation might be explained by different experimental
conditions (overnight ELISpot assay compared to a 5 day
proliferation assay combined with the measurement of
IFN-g in the supernatant by ELISA), or by the difference
in the HLA frequencies of the South African Xhosa popula-
tion, where our experiments were performed. Computa-
tional prediction suggested that the middle region
between amino acids 30e50 of the Rv2654c protein to be
unrecognised by the Xhosa population and only the region
near the C-terminal section of the protein was predicted
to be immunogenic enough to show up in the analysis.
These results, together with the results of Sette and his
co-workers,36 who have also found discrepancy between
their study and earlier works, highlight the necessity of tak-
ing population dependent HLA restriction in antigen recog-
nition into account.
In terms of chemical considerations, p51-65 bears
further advantages compared to p38-55, such as being
more soluble and more stable under in vitro conditions.
These characteristics make peptide p51-65 that provoked
significantly increased IFN-g response in a whole blood
assay, a more convenient synthetic antigen.
Using synthetic peptide p51-65 in the QuantiFERON-TB
Gold In-Tube assay resulted in significant boosting of the
quantitative performance of the QFT test in the HIV
uninfected group. This increase in the IFN-g response is
most likely due to the presence of the additional epitope
recognised by antigen specific T cells, secreting IFN-g. As
the IFN-g is measured in the supernatant, the response is
additive, hence the increase. In the HIV infected cohort the
quantitative performance did not change at day 0 and 1
month into the initiation of antiretroviral treatment. How-
ever, 3 months of ART resulted in an enhanced proportion of
persons scoring positive in the boosted QFT assay, most
likely due to ART induced immune recovery and increased
CD4þ T-cell numbers, able to recognise additional epitopes.
Although the increased recognition was not statistically
(and thus also not clinically) significant, is in accordance
with the findings of Kellar and colleagues, who have demon-
strated that the combination of ESAT-6 and CFP-10 peptide
pools with the pool of overlapping peptides representing
Rv2654c protein, has resulted in a significantly greater
cytokine and chemokine response in TB patients using
whole-blood assay.37 Moreover, the reason for not seeing
a significant increase in median IFN-g responses in the HIV
infected individuals could be due to the relatively short
duration of follow up (6 months) on ART. In our previous
study38 we demonstrated that ART is associated with an ab-
solute increase in effector function (which is what is being
Figure 3 Population tailored epitope prediction. The portion of the population able to present a 15-mer peptide was estimated
based on simulations combining MHC binding scores of the IEDB epitope prediction tool and HLA serotype frequencies described in
the Xhosa population. The 5 best scoring peptides for a given combination of HLA alleles were regarded as binders (binding to an
APC), with a fair chance for antigen presentation. The number of people likely to have a given combination of HLA alleles was esti-
mated using the HardyeWeinberg equation. Percentage of the whole population, expected to present a given peptide is given for
each possible starting position of 15-mers derived from the Rv2654 protein. Panel (A) represents the percentage of the Xhosa pop-
ulation, expected to present 15-mer peptides, based on both HLA-DR and HLA-DQ predictions of the IEDB tool. On panel (B), per-
centage of Xhosa population based only on HLA-DR prediction is presented, while on panel (C), percentage of the Danish
population, based on HLA-DR predictions is represented.
Table 3 Recognition and boosting effect of p51-65 in the HIV negative cohort.
QFT performance QFTB performance
Number tested n Z 55 55
Median IU/ml (IQR)a 1.83 (0.32e6.90) 2.83 (0.32e11.54)
Comparison of median IU/ml responseb ** (p Z 0.002)
No. of positive respondersc 40 41
Responders %d 73 75
Sensitivity % (95% CI)e 95 (83.8e99.4) 98 (87.1e99.9)
Blood samples of 55 HIV uninfected participant were assayed in commercially available QFT and p51-65 peptide boosted QFT (QFTB). The
cut-off for positive recognition was 0.35 IU/ml above nil.
a Median IU/ml value in QFT or QFTB assay and interquartile range.
b Significance was calculated using Wilcoxon matched pairs test. **p < 0.01.
c Number of positive responders/number tested.
d Percentage of responders out of all donors tested.
e Sensitivity was calculated as a ratio of the number of true positive responders over the number of false negative plus true positive
responders. False negativity was confirmed by ELISpot using ESAT-6/CFP-10 antigens. The difference in sensitivity statistically is not
significant.
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Table 4 Recognition and boosting effect of p51-65 in the HIV infected cohort.
Day 0 n Z 441 1 Month n Z 41 3 Months n Z 42 6 Months n Z 39
QFT performance
Median IU/ml (IQR)a 1.17 (0.26e7.14) 1.74 (0.09e11.63) 0.57 (0.07e6.89) 1.20 (0.10e4.53)
No. pos. resp.b 30 28 24 22
Responders %c 68 68 57 56
Sensitivity % (95% CI)d 97 (83.3e99.9) 97 (82.2e99.9) 80 (61.4e92.3) 81 (61.9e93.7)
QFTB performance
Median IU/ml (IQR)a 1.17 (0.05e6.11) 1.16 (0.09e17.90) 0.70 (0.15e5.78) 1.19 (0.14e4.46)
No. pos. resp.b 28/44 27 27 25
Responders %c 64 66 64 64
Sensitivity % (95% CI)d 90 (74.3e98.0) 93 (77.2e99.2) 90 (73.5e97.9) 93 (75.7e99.1)
Viral load Median (IQR) 71,291 (38,855e2,27,729) 316 (114e593) 39 (39e77) 39 (39e39)
CD4þ T cell number Median
(IQR)
197 (121e238) 278 (185e340) 298 (189e363) 307 (247e399)
HIV infected participants were sampled before the initiation of ART and 1, 3 and 6 months after the treatment. Blood samples were
assayed in commercially available QFT and p51-65 peptide boosted QFT (QFTB). The cut-off for positive recognition was 0.35 IU/ml
above nil.
a Median IU/ml value in QFT or QFTB assay and interquartile range.
b Number of positive responders/number tested.
c Percentage of responders out of all donors tested.
d Sensitivity was calculated as a ratio of the number of true positive responders over the number of false negative plus true positive
responders. False negativity was defined for those who had at least one positive result before. There was a statistically non-significant
trend of increasing sensitivity at 3 and 6 months for QFTB compared to QFT.
186 K. Horvati et al.measured by IGRA), but the proportional response
decreased over 1 year of ART, and the strongest correlate
of increased ART-mediated immunity was the central mem-
ory response. Thus, in the expanding CD4 T cell pool, con-
taining antigen specific T cells that are potentially able to
recognise the additional antigen, these cells are not high
enough in numbers to reflect an increase in IFN-g responses
at 6 months of ART.
Overall, different ethnic populations may respond to
different peptides than what is available in the commercial
IGRA, but the overall effect is a modest increase in
responders and not likely to change current assay pro-
cedures. While our data are preliminary and warrant
further validation with different epitopes, we can conclude
that it shows promise for population tailored detection of
MTB sensitization and for promiscuous synthetic epitope
peptides of proteins such as Rv2654c to be considered as
part of more effective immunodiagnostics.
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